Podcasts about mindmed

“This isn’t just an incremental shift, it’s a drastically different treatment dynamic,” says Rob Barrow, CEO of MindMed. On this episode of Vanguards of Health Care, Barrow speaks with Bloomberg Intelligence analyst Jean Rivera Irizarry about how MM120, a pharmaceutically optimized form of LSD, could transform the treatment landscape for anxiety and depression. They explore MindMed’s unique no-therapy approach to psychedelic trials, the design of its pivotal Phase 3 studies, and how it’s navigating regulatory hurdles to bring this once-taboo drug class into the mainstream.See omnystudio.com/listener for privacy information.

Berkshire's cash hoard is approaching “Dr. Evil” levels. (00:21) Tim Beyers and Dylan Lewis discuss: - Warren Buffett's message to investors and Berkshire Hathaway shareholders in his annual letter. - Berkshire's growing cash position and what it might say about his view of the investing opportunities out there. - Apple's $500B commitment to its Advanced Manufacturing Fund, AI development, and R&D efforts. (16:33) American's pharmaceutical options for legally treating mental health issues could expand soon. MindMed is testing the effects of LSD on depression and Anxiety, the company's CEO Rob Barrow talks Ricky Mulvey through his company's work and the future of psychedelics and mental health. Companies discussed: BRK.A, BRK.B, AAPL, MNMD Host: Dylan Lewis Guests: Tim Beyers, Rob Barrow, Ricky Mulvey Producer: RIcky Mulvey Engineers: Dan Boyd, Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices

Jessie Hopkins has over 17 years of professional experience, including working for renowned cellist Yo-Yo Ma. She currently serves as Senior EA to the CEO at MindMed.In this episode of The Leader Assistant Podcast, Jessie talks about what she learned working for a grammy winning cellist, the value of an EA coach and community, staying motivated while working remotely, working in a field you're passionate about, and more!Show notes -> leaderassistant.com/299Sponsor -> leaderassistant.com/nova--Nova Chief of Staff's course provides you with the knowledge and confidence you need to stand out on the job. Whether you want to land your dream position or level up in your current role, Nova's self-paced course gives you hands-on practice doing what Chiefs of Staff do every day.Visit leaderassistant.com/nova to enroll before the price increases in January 2025!More from The Leader Assistant... Book, Audiobook, and Workbook -> leaderassistantbook.com Premium Membership -> leaderassistant.com/membership Events -> leaderassistantlive.com Free Community -> leaderassistant.com/community

Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD and Lykos Therapeutics (1:35). Recent news a blessing in disguise for Cybin, COMPASS Pathways and MindMed (14:30)? Trial data and cash in the bank are top signifiers of success (22:35). How Atai fell behind and dropped out of the conversation (24:00). Upcoming catalysts - patience required (26:35). For psychedelic medicine, does it matter who's in the White House (29:30)?Read episode transcriptsShow Notes:FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks UnchangedMindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating FactorsATAI: Enormous Potential Upside But No Clarity YetDe-Risking Psychedelics: Compass Pathways, Cybin And AtaiFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

The big news of this week so far was Monday's FDA advisory committee for Eli Lilly's Alzheimer's drug donanemab, where the vote was unanimous in support of the anti-amyloid antibody. If approved, donanemab would be a direct competitor of Biogen and Eisai's Leqembi, but analysts believe there's plenty of room in the market for both, and even predict that donanemab's potential approval could be beneficial for Leqembi in the long run by increasing investments in advocacy and infrastructure. The mood was decidedly different from last week's FDA adcomm, which voted overwhelmingly against approving Lykos Therapeutics' MDMA-assisted PTSD therapy. Interestingly, that vote came down less an hour before BioSpace Senior Editor Heather McKenzie hosted a panel at BIO where Dan Karlin, chief medical officer at MindMed, said he'd hoped the conversation would have been different. In other conference news, Eli Lilly and partners Boehringer Ingelheim and Zealand Pharma presented mid-stage results for their GLP-1 products in the MASH space at the Congress of the European Association for the Study of the Liver. These companies are eyeing a piece of the MASH market that Madrigal Pharmaceuticals first tapped into earlier this year when its therapy, Rezdiffra, was approved in March. Finally, CBRE published a report on challenges in finding R&D and manufacturing talent, and thousands of layoffs continue to hit the biopharma industry. According to our Layoff Tracker, there have been 14,000 positions cut this year, with BMS and Bayer being the unfortunate leaders, each with more than 1,500 layoffs underway. Still, analysts are optimistic that the second half of 2024 could be better, as an uptick in the financial markets might provide companies with money to spend on growing their workforces.

Analyst Alex Carchidi discusses positive news coming out of psychedelic space (1:00). Recent earnings show companies moving closer to commercialization (3:35). Cybin and Atai developments; clinical studies and regulatory relief (5:25). Why now is the time to get into the space; ranking Compass and MindMed above the rest (8:00). Proper metrics and diversified pipelines (10:20).Show Notes:Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatmentDe-Risking Psychedelics: Compass Pathways, Cybin And AtaiPsychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.COMPASS Pathways Q1 2024 Earnings Call TranscriptEpisode transcriptsFor full access to analyst ratings, stock quant scores as well as dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptionsRegister for Seeking Alpha's Investing Summit (with your podcast discount code!)

In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining MindMed as Chief Development Officer in January 2021, he was named CEO in June 2021. Mr. Barrow has a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude and is a CFA charterholder.Last month, MindMed received FDA Breakthrough Therapy Designation for its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD).The company also announced that a Phase IIb study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/  Follow Us on Social MediaTwitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

This week we're talking about Beverly Hills 90210, insulin cows, MindMed, and Black Cat. Show music by HeartBeatHero and OGRE. Support the show! Joe's Linktree Get up to 2 months free podcasting service with our Libsyn code OZONE

Show Notes  DON'T MISS THIS EPISODE! Our fascinating guest today is a game-changer in progressive psychiatric treatments to manage mental issues like anxiety and depression and ADHD.  Dan Karlin is the Chief Medical Officer of a company called MindMed, whose mission is to improve patient outcomes by unlocking the full therapeutic potential of psychedelics and other novel therapeutic targets.  So yes. Today's show is all about psychedelics and improvements in mental health.   As a hippie in the 1960's I am not unfamiliar with LSD and psilocybin. So I have plenty of questions. Dan has plenty of responses.   Just a bit on our guest: Dr Dan Karlin joined MindMed as Chief Medical Officer in February 2021 following MindMed's acquisition of HealthMode, the company he co-founded and led as CEO. Prior to HealthMode, Dan served as the Global Clinical Lead at Pfizer. He is Board certified in Psychiatry and Addictive Medicine.  In other words, Dan Karlin knows what he is talking about. So, let's bring him on the show.  LINKS Click HERE to learn more about Dan Karlin and MindMed (at mindmed.co)  

Straight from Benzinga newsdesk, hosts Brent Slava and Michael O'Connor bring you the market news and stocks to watch.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659STOCKS TO WATCH: $MSFT $DRI $AVAV $MNMD $HOURMicrosoft (MSFT) - Analysts at JP Morgan raised their price target on Microsoft from $315 to $350 Thursday morning. As Microsoft shares traded around the $337 level most recently, the new JP Morgan price target represents only a few percent of upside to the JP Morgan price target. To hear more about the importance (or rather lack of importance) of this call, tune into Benzinga's Stocks To Watch podcast around market open time on Twitter. Darden Restaurants (DRI) - The owner of Olive Garden, Bahama Breeze and LongHorn Steakhouse. The company will report quarterly results on Thursday, June 22. AeroVironment (AVAV) - A play on unmanned aerial vehicle systems and drones. Analysts at Jefferies began coverage on AeroVironment Thursday morning with a Buy rating and $115 price target. MindMed (MNMD) - A play on the psychedelics space. MindMed will host an investor day event on Thursday, June 20 at 9:30 a.m. EDT. Hour Loop (HOUR) - One of Thursday's low-float, penny-stock momentum plays. Shares were up nearly 15% on no news.Did someone forward you this email? Click here to get your own copy, delivered hot and fresh to your inbox every morning. Hosts:Brent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga NewsdeskMichael O'Connor Reach out to Michael at michaeloconnor@benzinga.comBenzinga Strategy Developmentpro.benzinga.comIf you have ideas for stocks we should cover or have feedback about the info or presentation, please drop us a line at newsdesk@benzinga.com or aslicoskun@benzinga.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Nick talks to Daniel Karlin, MD, a board-certified physician in psychiatry, addiction medicine & clinical informatics who is the Chief Medical Officer at MindMed. They discuss: psychiatry; incentives in scientific & medical research; healthcare & mental health; psychedelics; LSD for anxiety; MDMA for autism; ibogaine derivatives for addiction; patient access & care; and more.Try Everyday Dose, high-quality coffee & matcha alternatives with functional mushrooms & other supplements.Support the showSign up for the free weekly Mind & Matter newsletter:[https://mindandmatter.substack.com/?sort=top]Learn how you can further support the podcast: [https://mindandmatter.substack.com/p/how-to-support-mind-and-matter]Become a Premium Subscriber to access full content library, including full premium episodes:[https://mindandmatter.substack.com/subscribe?utm_source=menu&simple=true&next=https%3A%2F%2Fmindandmatter.substack.com%2F]Try the Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for $50 off:[https://www.lumen.me/shop?fid=8731&utm_source=influencer&utm_medium=influencer&discount=MIND]

In today's episode of the Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Dan Karlin. Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He currently serves as the Chief Medical Officer of MindMed, a drug development company striving to deliver on the therapeutic potential of psychedelics to address unmet patient needs in psychiatry, addiction, pain, and neurology. Numinus is a trial site for MindMed's MM-120 or LSD dose-finding study for the treatment of anxiety symptoms, so they discuss that study and what LSD treatment might look like in a post-approval clinical context. They discuss the challenges of mental health care accessibility and affordability, explore the philosophy behind the psychiatric diagnostic system, talk about the societal burden of anxiety, compare and contrast anxiety vs depression, and much more.Come and attend the MAPS Psychedelic Science 2023 conference, Numinus is offering an exclusive 20% discount code to our PTF Podcast listeners. To get 20% off the  registration price, click this link (https://bit.ly/3kzoofk) and use the code NWI20 at checkout.Learn more about our psychedelic training programs at HERE and use code PTF10 at checkout for 10% off! (2:35) Dr. Dan Karlin introduces himself and psychedelic studies(13:34) The path to psychedelic approval(16:37) Why anxiety?(21:42) Why LSD?(24:51) MM-120 and accessibility(33:21) The burden of anxiety in society(50:44) MindMed updatesLearn more about our podcast at https://numinus.com/podcast/Learn more about psychedelic therapy training opportunities at https://numinus.com/our-training-selection/Learn more about Numinus at https://numinus.com/Follow us on Instagram: https://www.instagram.com/drstevethayer/https://www.instagram.com/innerspacedoctor/https://www.instagram.com/numinushealth/

Dr. Daniel Karlin, Chief Medical Officer at MindMed, is bringing an updated approach to developing an LSD-based drug to treat anxiety and depression. Instead of developing a psychiatric medicine to be taken every day, MindMed is changing the paradigm to a session-based therapy that uses psychedelic drugs and therapists to improve psychiatric health. As a trained psychiatrist, Dan works at the intersection of psychiatry and neuroscience with this psychedelic-assisted therapeutic approach to brain health.  Dan elaborates, "For quite some time, I think it feels like psychiatry hasn't been meeting people there. Treatments have been more focused on symptomatic resolution and these sorts of things, and visits with psychiatrists can feel too short and it can be really hard to find and afford psychotherapy. I think that what people are responding to about LSD and other drugs like it and their therapeutic potential is the sense that they offer something more than what people are able to access today. That there's real hope that these are drugs that can help people get at the real reasons they feel the way they feel and come to understand themselves better and their role in the world." "There's another school of thought that the mechanism of these drugs is largely neurobiological and that the perceptual experience may not even be necessary. Of course, anytime we start to do binaries in biology, we're probably wrong. And it's probably some of both. And we operate under that hypothesis too, that the mechanism by which these drugs cause a psychedelic experience is very well explicated. The mechanism by which they cause lasting change isn't." @MindMedco #MNMD $MNMD #PsychedelicMedicines #PsychedelicTherapy #LSD #Psychedelics #MentalHealth #BrainHealth #PsychiatricHealth  mindmed.co Listen to the podcast here

Dr. Daniel Karlin, Chief Medical Officer at MindMed, is bringing an updated approach to developing an LSD-based drug to treat anxiety and depression. Instead of developing a psychiatric medicine to be taken every day, MindMed is changing the paradigm to a session-based therapy that uses psychedelic drugs and therapists to improve psychiatric health. As a trained psychiatrist, Dan works at the intersection of psychiatry and neuroscience with this psychedelic-assisted therapeutic approach to brain health.  Dan elaborates, "For quite some time, I think it feels like psychiatry hasn't been meeting people there. Treatments have been more focused on symptomatic resolution and these sorts of things, and visits with psychiatrists can feel too short and it can be really hard to find and afford psychotherapy. I think that what people are responding to about LSD and other drugs like it and their therapeutic potential is the sense that they offer something more than what people are able to access today. That there's real hope that these are drugs that can help people get at the real reasons they feel the way they feel and come to understand themselves better and their role in the world." "There's another school of thought that the mechanism of these drugs is largely neurobiological and that the perceptual experience may not even be necessary. Of course, anytime we start to do binaries in biology, we're probably wrong. And it's probably some of both. And we operate under that hypothesis too, that the mechanism by which these drugs cause a psychedelic experience is very well explicated. The mechanism by which they cause lasting change isn't." @MindMedco #MNMD $MNMD #PsychedelicMedicines #PsychedelicTherapy #LSD #Psychedelics #MentalHealth #BrainHealth #PsychiatricHealth  mindmed.co Download the transcript here

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. He shares what investors should focus on in the psychedelic space and the pros and cons of owning his top 5 psychedelic stocks.

LinkedIn: https://www.linkedin.com/in/cole-butler/ Website: https://www.lionheartwellness.net/ LSD for Anxiety email: cole@focogad.com Private Practice email: colionheart@gmail.com Cole is a Psychedelic Research Coordinator in Fort Collins, Colorado. He works as a ketamine-assisted psychotherapy intern at Wholeness Center, conducting groups and individual ketamine sessions. He also coordinates an LSD for Anxiety clinical trial through MindMed, where he is also a trained Dosing Session Monitor. He is a coach and consultant for careers in psychedelics and cannabis recovery through his private practice, Lionheart Wellness. Schedule a mentoring session: Work with Me | LMC (lmcolletti.com) Check out this interview on Youtube: https://youtu.be/yWAq6gTnjM4 Love is Insanity available now: https://www.barnesandnoble.com/w/love-is-insanity-lauren-michelle-colletti/1142444388 Find my books here: amazon.com/author/laurenmcolletti Connect with me on Instagram: @laurenmcolletti We all know it's important to engage in physical activity to keep our bodies healthy and strong. But even the best workout regimen can result in tightness, soreness and pulled or strained muscles. That's why I use Nuume CBD cream as part of my post exercise, self care routine to relieve tenderness, aches and pains Nuume relief extra strength salve contains 1500 mg of CBD. It's USDA organic certified, vegan, gluten-free and kosher with No artificial flavors or preservatives. A small amount goes a long way and a jar can even last over a year. This salve keeps my muscles loose and relaxed, resulting in quicker recovery time and higher endurance to keep me going. Check it out for yourself: https://globalgreenexpress.com/products/relief-salve-extra-strength. --- Send in a voice message: https://anchor.fm/lauren-colletti/message

Welcome to the 2nd episode of Psychedelic Sunday, where we delve into psychedelics and investing. Today we give an overview of the 4 main stocks in psychedelics, focusing on recent earnings calls and analyst Q&A for Compass Pathways (CMPS), Atai Life Sciences (ATAI), MindMed (MNMD) and Cybin (CYBN). We'll be diving even deeper into these stocks over the next couple of weeks with the help of Stephen Tobin and Alexander Carchidi.

Welcome to the first ever Psychedelic Sunday episode! There is a lot of overlap between cannabinoid and psychedelic experiences and today we launch our coverage of the psychedelics industry. Challenges and opportunities within psychedelics; highlighting four stocks: Compass Pathways (NASDAQ:CMPS), Cybin (NYSE:CYBN), Atai Life Sciences (NASDAQ:ATAI), and MindMed (NASDAQ:MNMD).

Speakers: Sandeep Bhat, Senior Leader, Digital Health Partnerships and Digital Engagement, Global Clinical Operations, GSKDan Karlin, MD, CMO, MindMed

Host: Jennifer Caudle, DO Guest: Daniel R. Karlin, MD, MA Digital tools have emerged as one of the newest therapeutic modalities for behavior modification in several chronic psychiatric diseases,1 such as major depressive disorder, chronic insomnia, and substance use disorders. But what exactly are these digital tools, and what does their use look like in practice? Joining Dr. Jennifer Caudle to answer those and other key questions regarding the use of digital tools in psychiatry is Dr. Daniel Karlin, Assistant Professor of Psychiatry at Tufts University in Boston and Chief Medical Officer at MindMed in New York City. References: Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med. 2020;3:159. August 2022 US.UNB.X.22.00018

In this week's episode of Healthspan Academy, I had a fascinating chat with Dr Dan Karlin about the latest info on the applications of psychedelics for improving cognitive function and mental health. We talked about the most common outcomes, proper dosing, and designing the ideal environment and experience. Dr. Karlin summarized what we currently know about the mechanism and the relation to our neurotransmitters and neuroplasticity. We also talked about future applications and when we could expect some of these psychedelics to come to market.  Dr. Dan Karlin joined MindMed as Chief Medical Officer in February 2021 following MindMed's acquisition of HealthMode, the company he co-founded and led as CEO. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine. Dr. Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics working at the intersection of health and technology in the pharmaceutical and biotech industry on psychiatric drug development, novel instruments, data, and analysis-driven strategies for clinical drug development; and in clinical medicine where he practices psychiatry and addiction medicine, teaches clinical skills and quality improvement, develop novel technologies, and creates tech-enabled care models and practices. Prior to joining HealthMode, he established and led Pfizer's Digital Medicine and Innovation Research Lab's clinical, informatics, and regulatory strategy. He also worked at Pfizer as the Global Clinical Lead for psychiatry clinical compounds. He previously served as Column Health's founder and Chief Medical Officer, a leading technology-enabled psychiatry and addiction practice. Dr. Dan serves as a strategic advisor to several pharmaceutical, biotech, and health technology firms. He is also a founding Advisor to the Digital Biomarkers Journal, the founder and Board Member of the Digital Medicine Society (DiMe), and a member of the Critical Path Alzheimer's Disease, MJFF, and Mental Health IT committees at the APA. Currently, he is also an Assistant Professor of Psychiatry at Tufts University School of Medicine. Find out more about Dr. Dan on the MindMed website at www.mindmed.co. *** Please note that the content discussed in this podcast is intended for self-education and is not to be interpreted as medical advice.

Hugh T Alkemi, host of EntheoRadio, is honored for a second time with Psychedelic Research Renaissance Founding Father Rick Strassman, MD who has been on The Joe Rogan Experience just this month and on Entheoradio about two years ago. It's always a fun time discussing the impact of psychedelics from both a research and a cultural standpoint with Dr Rick. This show includes suggestions and speculations about consciousness and the ongoing hype filled, psychedelic trend in the United States and gets especially intense in the part two of this episode. This is part 1 of 2.Bio for Rick Strassman, MD:Rick Strassman was born in Los Angeles, California in 1952. He attended public schools in southern California's San Fernando Valley and graduated from Ulysses S. Grant High School in Van Nuys in 1969. As an undergraduate, he majored in zoology at Pomona College in Claremont California for two years before transferring to Stanford University, where he graduated with departmental honors in biological sciences in 1973. During summers in college, he worked for RedKen Laboratories, developing cosmetics and a line of hair dyes. In addition, he performed laboratory research at Stanford, on the development of the chicken embryo's nervous system. He attended the Albert Einstein College of Medicine of Yeshiva University in the Bronx, New York, where he obtained his medical degree with honors in 1977.Dr. Strassman took his internship and general psychiatry residency at the University of California, Davis, Medical Center in Sacramento, and received the Sandoz Award for outstanding graduating resident in 1981. After graduating, he worked for a year in Fairbanks, Alaska in community mental health and private psychiatric practice. From 1982-1983, he obtained fellowship training in clinical psychopharmacology research at the University of California, San Diego's Veteran's Administration Medical Center. He then served on the clinical faculty in the department of psychiatry at UC Davis Medical Center, before taking a full-time academic position in the department of psychiatry at the University of New Mexico School of Medicine in Albuquerque in 1984.At UNM, Dr. Strassman performed clinical research investigating the function of the pineal hormone melatonin in which his research group documented the first known role of melatonin in humans. He also began the first new US government approved clinical research with psychedelic drugs in over twenty years, focusing on DMT and to a lesser extent, psilocybin. He received grant support from the National Institutes of Health's National Institute on Drug Abuse, as well as from the Scottish Rite Foundation for Schizophrenia Research. Before leaving the University in 1995, he attained the rank of tenured Associate Professor of Psychiatry and was awarded the UNM General Clinical Research Center's Research Scientist Award.In 1984, he received lay ordination in a Western Buddhist order, and co-founded, and for several years administered, a lay Buddhist meditation group associated with the same order. Dr. Strassman underwent a four-year personal psychoanalysis in New Mexico between 1986 and 1990.From 1996 to 2000, while living in the Pacific Northwest of the United States, Dr. Strassman worked in community mental health centers in Washington State in Bellingham and Port Townsend. For the next four years, he had a solo private practice in Taos, New Mexico. After two years working near the Navajo Nation in Gallup NM, he returned to northern New Mexico in 2006, where he provided psychiatric services at a mental health center in Espanola. Since mid-2008, he has been writing full-time.Dr. Strassman's “DMT: The Spirit Molecule,” an account of his DMT and psilocybin studies, has sold a quarter-million copies as of mid-2021, and been translated into over a dozen languages, including Mandarin. He co-produced an independent documentary by the same name, which was the most-streamed independent drug documentary on Netflix. He also is the author of “DMT and the Soul of Prophecy,” “Joseph Levy Escapes Death,” and a co-author of “Inner Paths to Outer Space.”He has published over 40 peer-reviewed scientific papers and has served as a reviewer for 20 psychiatric research journals. He has been a consultant to the US Food and Drug Administration, National Institute on Drug Abuse, Veteran's Administration Hospitals, Social Security Administration, and other state and local agencies. He has provided consultation to many of the psychedelic startups that began appearing in 2020, including Atai, MindMed, and The Noetic Fund. He is on the Scientific Advisory Boards for Alexander Shulgin Research Institute and Ninnion Therapeutics.He currently is Clinical Associate Professor of Psychiatry at the University of New Mexico School of Medicine and lives in Gallup, New Mexico.ENTHEORADIO IS SPONSORED BY:Mushroom Shaman Brand Supplements and ServicesHttps://linktr.ee/mushroomshaman/Alkemi Ormus Products and ExtractsAlkemi.gold Buy his book through his site to get a personal inscription: https://www.rickstrassman.com/publications/the-psychedelic-handbook/The Psychedelic Handbook:Entering the world of psychedelic drugs can be challenging, and many aren't sure where to start. As research continues to expand and legalization looms on the horizon for psychedelics like psilocybin, you may need a guide to navigate what psychedelics are, how they work, and their potential benefits and risks.The Psychedelic Handbook is a complete manual that is accessible to anyone with an interest in these “mind-manifesting” substances. Packed with information on psilocybin, LSD, DMT/ayahuasca, mescaline/peyote, ketamine, MDMA, ibogaine, 5-methoxy-DMT (“the toad”), and Salvia divinorum/salvinorin A, this book is your ultimate reference for understanding the science and history of psychedelics; discovering their potential to treat depression, PTSD, substance abuse, and other disorders, as well as to increase wellness, creativity, and meditation; learning how to safely trip and explaining what we know about microdosing; and recognizing and caring for negative reactions to psychedelics.Clinical research psychiatrist, father of the American psychedelic research renaissance, and best-selling author of DMT: The Spirit Molecule, Dr. Rick Strassman shares his experience and perspectives as neither advocate nor foe of psychedelics in order to help readers understand the effects of these remarkable drugs.

Hugh T Alkemi, host of EntheoRadio, is honored for a second time with Psychedelic Research Renaissance Founding Father Rick Strassman, MD who has been on The Joe Rogan Experience just this month and on Entheoradio about two years ago. It's always a fun time discussing the impact of psychedelics from both a research and a cultural standpoint with Dr Rick. This part 2 of 2 of the interview becomes particularly intense and includes both powerful wisdom and cautionary speculation about the future of Psychedelics in the USA.Bio for Rick Strassman, MD:Rick Strassman was born in Los Angeles, California in 1952. He attended public schools in southern California's San Fernando Valley and graduated from Ulysses S. Grant High School in Van Nuys in 1969. As an undergraduate, he majored in zoology at Pomona College in Claremont California for two years before transferring to Stanford University, where he graduated with departmental honors in biological sciences in 1973. During summers in college, he worked for RedKen Laboratories, developing cosmetics and a line of hair dyes. In addition, he performed laboratory research at Stanford, on the development of the chicken embryo's nervous system. He attended the Albert Einstein College of Medicine of Yeshiva University in the Bronx, New York, where he obtained his medical degree with honors in 1977.Dr. Strassman took his internship and general psychiatry residency at the University of California, Davis, Medical Center in Sacramento, and received the Sandoz Award for outstanding graduating resident in 1981. After graduating, he worked for a year in Fairbanks, Alaska in community mental health and private psychiatric practice. From 1982-1983, he obtained fellowship training in clinical psychopharmacology research at the University of California, San Diego's Veteran's Administration Medical Center. He then served on the clinical faculty in the department of psychiatry at UC Davis Medical Center, before taking a full-time academic position in the department of psychiatry at the University of New Mexico School of Medicine in Albuquerque in 1984.At UNM, Dr. Strassman performed clinical research investigating the function of the pineal hormone melatonin in which his research group documented the first known role of melatonin in humans. He also began the first new US government approved clinical research with psychedelic drugs in over twenty years, focusing on DMT and to a lesser extent, psilocybin. He received grant support from the National Institutes of Health's National Institute on Drug Abuse, as well as from the Scottish Rite Foundation for Schizophrenia Research. Before leaving the University in 1995, he attained the rank of tenured Associate Professor of Psychiatry and was awarded the UNM General Clinical Research Center's Research Scientist Award.In 1984, he received lay ordination in a Western Buddhist order, and co-founded, and for several years administered, a lay Buddhist meditation group associated with the same order. Dr. Strassman underwent a four-year personal psychoanalysis in New Mexico between 1986 and 1990.From 1996 to 2000, while living in the Pacific Northwest of the United States, Dr. Strassman worked in community mental health centers in Washington State in Bellingham and Port Townsend. For the next four years, he had a solo private practice in Taos, New Mexico. After two years working near the Navajo Nation in Gallup NM, he returned to northern New Mexico in 2006, where he provided psychiatric services at a mental health center in Espanola. Since mid-2008, he has been writing full-time.Dr. Strassman's “DMT: The Spirit Molecule,” an account of his DMT and psilocybin studies, has sold a quarter-million copies as of mid-2021, and been translated into over a dozen languages, including Mandarin. He co-produced an independent documentary by the same name, which was the most-streamed independent drug documentary on Netflix. He also is the author of “DMT and the Soul of Prophecy,” “Joseph Levy Escapes Death,” and a co-author of “Inner Paths to Outer Space.”He has published over 40 peer-reviewed scientific papers and has served as a reviewer for 20 psychiatric research journals. He has been a consultant to the US Food and Drug Administration, National Institute on Drug Abuse, Veteran's Administration Hospitals, Social Security Administration, and other state and local agencies. He has provided consultation to many of the psychedelic startups that began appearing in 2020, including Atai, MindMed, and The Noetic Fund. He is on the Scientific Advisory Boards for Alexander Shulgin Research Institute and Ninnion Therapeutics.He currently is Clinical Associate Professor of Psychiatry at the University of New Mexico School of Medicine and lives in Gallup, New Mexico.ENTHEORADIO IS SPONSORED BY:Mushroom Shaman Brand Supplements and ServicesHttps://linktr.ee/mushroomshaman/Alkemi Ormus Products and ExtractsAlkemi.gold Buy his book through his site to get a personal inscription: https://www.rickstrassman.com/publications/the-psychedelic-handbook/The Psychedelic Handbook:Entering the world of psychedelic drugs can be challenging, and many aren't sure where to start. As research continues to expand and legalization looms on the horizon for psychedelics like psilocybin, you may need a guide to navigate what psychedelics are, how they work, and their potential benefits and risks.The Psychedelic Handbook is a complete manual that is accessible to anyone with an interest in these “mind-manifesting” substances. Packed with information on psilocybin, LSD, DMT/ayahuasca, mescaline/peyote, ketamine, MDMA, ibogaine, 5-methoxy-DMT (“the toad”), and Salvia divinorum/salvinorin A, this book is your ultimate reference for understanding the science and history of psychedelics; discovering their potential to treat depression, PTSD, substance abuse, and other disorders, as well as to increase wellness, creativity, and meditation; learning how to safely trip and explaining what we know about microdosing; and recognizing and caring for negative reactions to psychedelics.Clinical research psychiatrist, father of the American psychedelic research renaissance, and best-selling author of DMT: The Spirit Molecule, Dr. Rick Strassman shares his experience and perspectives as neither advocate nor foe of psychedelics in order to help readers understand the effects of these remarkable drugs.

Straight from Benzinga newsdesk, host Brent Slava brings you the market news and stocks to watch.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659Hosts:Brent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga Newsdeskpro.benzinga.com$NVDA $ZM $BFAM $CMPS $BBIGNVIDIA (NVDA) - Will report quarterly results Wednesday next week. The company will likely report its earnings around 4:20 p.m. EDT.Zoom Video Communication (ZM) - The company will publish quarterly results on Monday, Aug. 22, 2022 after market close.Bright Horizons Family Solutions (BFAM) - An interesting play on the work from home trend. Morgan Stanley discussed the company and stock in a research note Thursday morning. Analysts at the firm called Bright Horizons shares their highest-conviction recommendation to gain some bearish exposure. To hear more details from the Morgan Stanley call, tune into Benzinga's daily Stocks To Watch podcast around 9:30 a.m. EDT on Twitter or after 10 a.m. on Spotify or Apple.COMPASS Pathways (CMPS) - A play on psychedelics. Shares of peer in the psychedelics space, MindMed (MNMD), traded up about 70% in pre-market action. The Benzinga Pro newsdesk team did not identify news to justify the move higher in MindMed. Shares of MindMed and COMPASS Pathways have been known to trade relatively correlated.Vinco Ventures (BBIG) - A favorite among the Benzinga Pro user community. Shares have more than doubled so far this week following news Monday of a partnership with AIPros for social media. Momentum has continued each day following the news.Use coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications. In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilocybin and is focused on anxiety disorders. Meanwhile, MindMed is focused using low doses of LSD to treat adult ADHD.  Our guests are Dr. Michael McDonnell (Diamond Therapeutics) and Dr. Dan Karlin (MindMed).In case you missed it: In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we discuss placebo effect and the results of a self-blinded placebo-controlled study with Balázs Szigeti from the Centre for Psychedelic Research at Imperial College London.Disclaimer: This is not investment advice and is for information and educational purposes only. Credits: Created by Greg Kubin and Matias SerebrinskyHost:  Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank

This is a replay of Jason Raznick's interview with Kevin O'Leary at the Benzinga Pyschedelics Conference.Jason and Kevin talk about:Psychedelics as an investment opportunityWhy Cannabis Industry Attracts 'Zero' Institutional DollarsThe Most Successful investmentsHosts:Jason RaznickTwitter: https://twitter.com/jasonraznickSign Up to Benzinga Pro today to receive most exclusive interviews, news and stock picks fast!https://pro.benzinga.com/Click here for more episodes of The RazReport.Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Transcript:BZ: I want to introduce the number-one shark Mr. Wonderful. Kevin O'Leary. When did you first get into the psychedelic space? 3 years ago. I was here and a young guy came to me and said, look, I want you to give me a few million bucks to invest in psychedelics.I said, are you out of your mind? That's an illegal substance.He said, no, I want to do FDA trials with it. And it was a very fascinating conversation because at that time everybody was trying to raise money for Bitcoin. It was very crypto oriented and I really got interested and I put a couple of guys with him to do some diligence.And Alex one of the guys that works with me, Alex rarely gets excited about anything. He's seen everything. He's just came back and said listen we got to own this thing. The potential here is huge. And he was right. The addressable markets are in the hundreds of billions of dollars.BZ: And so where is Mindmed right now?K: When I index a sector, I try and mitigate my risk based on trials. In biotech medicine, the outcomes are unknown. So it's very binary. You can chase a molecule for 10 years and you in stage three lose.And so you have to have multiple trials. I'm overweight MindMed, but I also have exposure to Compass. They're all doing things slightly differently, but they're all in stage two. And The minute one of them gets to stage three on any medicine, you're going to lift all the tides, so you want multiple exposure.BZ: How did you decide to get into psychedelics?K:How many times in your investment life, do you get to position yourself in a brand new sector?A completely brand new sector? Never is the answer. You've once in a lifetime, if you're lucky. And this sector, and I'm not talking about cannabis, right? And I'm talking about psychedelics as medicine, FDA approved trials, non recreational use. Remember what happened back in the early sixties, the whole movement overdosing LSD caused this to be elevated to a narcotic and put aside, even though there's lots of promising evidence that micro-dosing, it could have some good natural attributes.In terms of helping people with addiction, opioid addiction, alcoholism, anxiety, all of these different massive markets. It was ignored. And then we've tried all these other drugs like pumping kids full Ritalin and all this garbage. And we haven't explored this opportunity. And I think now we are.And so for me, it's okay. There's been nothing new for 30 years in mental health. Other than just drugging people with more drugs. This looks more interesting. Let's put some dollars aside for this.BZ: Are you invested in cannabis companies? K: Let's talk about what cannabis is. Cannabis is a narcotic and that puts it in a difficult place for institutional investors.If you have two states beside each other, one has legalized cannabis and the other hasn't and you are a shareholder. Somebody takes it across the border. and now you have aided and embedded transferring a narcotic that's punished by about 23 years in jail. I'm not that interested in that outcome for me.Why don't we just get it off the narcotic list?And so I represent institutional capital. We're always trying to put money to work but there isn't a dime of institutional money in cannabis industry.Recreational cannabis is great, but it's a nothing burger compared to what this would be if it was a medicine and the potential of THC in small amounts or medicinal amounts, be FDA trials, and then approved as a drug that would have been interesting for institutions. And I think frankly, and I look at markets like Ontario, as you mentioned, the most advanced market. That business sucks. They don't allow them to brand anything. So the people in Ontario simply buy it from their dealers at a 30% discount and nothing's changed and it's a miserable business. So that's not a great investment at all. And the PEs of those stocks have been crushed.You can't get me excited about that.BZ: So your point is people in Ontario aren't going to the stores as much. They're going right to the direct source. Their dealers basically?K: Now, either you arrest all the dealers and throw them in jail, like we've been doing forever, except that's a problem now because it's legal. So now you have to figure out the distribution channels in Canada, they don't allow branding. So THC is THC, whether it's an, a gummy or an edible or you're buying it in smokable.There's no differentiation. So the people that are making that are selling a commodity and their margins are getting crushed. I don't find any of this very exciting as an investor. I think in a conference like this industry should do some soul searching and say, how do we fix this? And you start by convincing the president to get it off the narcotic list.And you bring in billions of dollars into it for both medicinal and recreational. After you get it off the narcotic list. That's cannabis. That's not the problem with the psychedelics industry, it still can attract institutional capital.BZ: When is big pharma going to get in the psychedelic space?I think big pharma is starting to look at it because you're trying to figure out outcomes on massive addressable markets. And the way I view it is this is a personal opinion, but I look at this market, all the companies are going to to have to merge because they need each other and another $200 million.By the time they get this to a medicine, that's about a billion bucks. They've got a raise it's much better if they combined all these trials together. In my view, these companies all have their own management. I know them all. I, we talked about this two years ago. I said, guys, there's so much still to be raised here, but so much potential.We could get strategic in this thing. Let's merge them all together. That's not how they viewed it. So I own stock in all of them.BZ: You think there is gonna be one winner or you might maybe a big merger of all three? Do we have some breaking news here?K: No you've got the LSD crowd, the microdosing crowd and a lot of skepticism around that, but a lot of optimism too, depending on who you talk to, you've got the psilocybin crowd, then you've got the alternative molecule where you're modifying either of those, each trying to address different afflictions around mental health.There's a lot of anecdotal information coming out of the west coast in the programming field, even though it's illegal, they're microdosing LSD, and there, which I don't endorse, but it's obviously got the research crowd really interested in understanding how this works and that's why those clinical trials are so important, but psilocybin also has potential as well.Plus there's the whole counseling market where you take these drugs in addition to it, to a counselor. So there's a lot of different use cases to this thing, but I'm far more constructive on psychedelics for institutional capital than I am for cannabis, for reasons I just detailed, don't shoot the messenger.Everybody was so excited about. Those stocks have come down 80% in PE since this whole thing started.BZ: What's your best business?K: Here's what I've learned about this whole shark tank thing. Somebody walks out in the carpet. I've never seen them before we give them a million dollars. We have no idea what the outcome's going to be.We think we've got a winner, but we don't know. And then two years later, some ridiculous product that should have gone to zero ends up selling for a hundred million dollars. And so I have a different view about it now.A woman walks out on the carpet. Jesus. You take a swab and you stick it in your cat's orifice and you send it to me and I give you a DNA profile of when fluffy is going to die. And I thought that is so stupid. I can't even imagine the test kits are $29 and you can get a new cat for $5. But I invested in any ways because she had such a great track record as an honorable. During the pandemic all of the110 million cats in America got something stuck up their rear end because that business has exploded and I was wrong, but I own a nice chunk of it. So I'm pretty happy.BZ: How many investments have you done? K: So you can take a product. The number one reason companies go to business and venture is they run out of dollars to acquire customers. They go bankrupt advertising, but when you're on shark tank, you acquire customers for free. So you can take a marginal business and all of a sudden it's profitable and shark tank because it's in syndication and perpetuity.So we make a lot of money on things. I don't know if you saw the recent episode, banana loca, you So you can now send a banana in your kid's lunchbox filled with peanut butter, but unpeeled, how does that work? You stick a catheter up a banana and then press peanut butter into it. I thought what a stupid idea and Alex backstage said I have to own that.And all of a sudden, all the big banana companies are calling us saying, Hey, can we do a deal? The stupidest idea I've ever seen it's crazy.Lori taught me something. Stupid things made of plastic sell a lot.Support this podcast at — https://redcircle.com/the-raz-report/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

On this episode of InsideOut, we chat with Rob Barrow, CEO of the pharma development company, MindMed. MindMed has been on a quest to bring psychedelic-inspired pharmaceuticals to mainstream healthcare, and Rob believes the time is right for a radical new approach to solving some of the most challenging mental health issues the world has ever faced.

In this epidose, we chat with Dan O'Brien, marketing manager for MindMed. MindMed is a biotech company that discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering. Together, we learn about the gaps in healthcare psychedelic-assisted therapies are filling, what MindMed is doing to expand and provide psychedelic treatments, and what role psychedelics will play in the future of healthcare. Resources: MindMed, Inc: https://mindmed.co/ Subscribe to SeroTunein: https://www.serotunein.com/podcast Music: ♪ Empty (Prod. by Lukrembo) Link : https://youtu.be/rd7vjgDJSGs ♪ Onion (Prod. by Lukrembo) Link : https://youtu.be/KGQNrzqrGqw

Optimised MDMA dosing, psychedelic precision medicine, LSD neutralising ... The landscape of psychiatry is changing fast. As traditional medicine continues to advance, and in order to combat the wave of mental health problems heightened by the Covid-19 pandemic, the industry is reconsidering forms of treatment previously disregarded.This session brings Robert Barrow, CEO of biotech company MindMed, into the conversation about how we can improve how we treat mental health issues. We'll also hear how specialised psychological therapy can be adapted into mainstream medical care.Web Summit will return to Lisbon in November 2022. Be part of the incredible event and pre-register for tickets today!Use promo code 'TNS' for 10% off your #CollisionConf ticket now. Support the show

We're back with part 2 of our Web Summit episode, bringing you conversations with people who are trying to make the world a better place. Today we talk with Sonia Jorge, Executive Director for Alliance for Affordable Internet and Head of Digital Inclusion Program at Web Foundation, to hear how they are creating the conditions for affordable Internet in countries worldwide and what they have learned along the way. Next, we sit down with Robert Barrow, the CEO of MindMed, a company that researches and develops psychedelic-inspired medicine, about what they see as the future of mental illness and addiction treatment. What Could Go Right? is produced by The Progress Network and The Podglomerate.

We talk with Marik Hazan, CEO of Tabula Rasa Ventures, about psychedelics for creativity, the impact of money on the industry. Plus Marik's take on the good, bad, and the ugly of the psychedelic industry.Highlights— THE NUGGET: California psychedelic legalization update (0:32)— THE NOODLE: single issue politics — legalize psilocybin (1:03)— Guiding 10% of the Yale MBA population on psychedelic retreats (3:56) — Laying healthy foundations for psychedelics (5:55)— MBA programs at Yale and UCLA supporting entrepreneurship (6:42)— The value of emotional support for entrepreneurs (9:40)— Two paths for the psychedelic renaissance (11:35)— How microdosing could fall into the SSRI trap (14:19)— Microdosing vs Macrodosing (18:27)— Meeting God on psychedelics (19:22)— Psychedelics for creativity, community, and flow state (22:18)— Shifting consciousness with cannabis (24:04)— SOUL SEARCH: a mystical experience with... Kanye West? (27:10)— SLAP and a CLAP: Mindset Pharma & MindMed (31:50)Find Marik here:Tabula Rasa Ventures — https://www.tabularasa.ventures/Instagram: @psychedstudioNew book: ourtriptogether.com---www.textpert.ai

Bruce Linton is a legend in the cannabis and psychedelics industries. He was the CEO of the world's largest cannabis company (Canopy Growth), was the first investor in MindMed, and is Chairman of the Advisory Board at Red Light Holland. Bruce joins The Integration Conversation to answer questions like: Why did Bruce Linton sell shares in MindMed? Why did JR leave MindMed? What's the difference between paid promotion & pump and dumps? Are psychedelics just cannabis 2.0? And more! Plus, Brom and Bruce talk about Empath Ventures. ❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc ⭐️ Become an Integration Insider and get early access to episodes: https://patreon.com/theintegrationco

Hello and welcome back to Equity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines.For this week's deep dive, Alex and Natasha and Danny decided that it was time to talk about drugs. No, not like drugs for fun, but instead drugs that you might have considered fun, but are now being redirected to help bolster your health.Yep, that's our theme today. As it turns out, there are a number of startups and even nascently public companies that are pursing using drugs that we might consider recreational for serious health purposes. Which is neat, as our habit of decrying any drug that makes you feel better as immoral has likely held us back from learning quite a lot about them.Venture capital investment in psychedelic start-ups, per CB Insights, rose from sub-$100 million results in 2018 and 2019 to $346 million last year.Vice clauses, however, can pause a legitimate issue for investors who might want to cut a check in the space.From the startup angle, NUE Life Health recently raised $3.3 million, and Osmind is up to some neat stuff regarding mental health.From the public markets, Atai Life Sciences, Compass Pathways, and MindMed are the companies worth watching.Frankly this was a fun one to record, even if the topic at hand is actually rather serious. Chat Friday morning!

Hello and welcome back to Equity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines.For this week's deep dive, Alex and Natasha and Danny decided that it was time to talk about drugs. No, not like drugs for fun, but instead drugs that you might have considered fun, but are now being redirected to help bolster your health.Yep, that's our theme today. As it turns out, there are a number of startups and even nascently public companies that are pursing using drugs that we might consider recreational for serious health purposes. Which is neat, as our habit of decrying any drug that makes you feel better as immoral has likely held us back from learning quite a lot about them.Venture capital investment in psychedelic start-ups, per CB Insights, rose from sub-$100 million results in 2018 and 2019 to $346 million last year.Vice clauses, however, can pause a legitimate issue for investors who might want to cut a check in the space.From the startup angle, NUE Life Health recently raised $3.3 million, and Osmind is up to some neat stuff regarding mental health.From the public markets, Atai Life Sciences, Compass Pathways, and MindMed are the companies worth watching.Frankly this was a fun one to record, even if the topic at hand is actually rather serious. Chat Friday morning!

Global strategy: Hyperinflation partly depends on the banks Inflation - Recent Data and when the rubber meets the road Bitcoin - El Salvador going all in on bitcoin AMC Teach-in - Why volatility is not your friend Stock warning signs - the MindMed example

Mind Medicine (MindMed) Inc (NASDAQ:MNMD, NEO:MMED) recently became the second public psychedelics company on a major US stock exchange. But from our discussions with CEO JR Rahn, MindMed have no intention of sitting in second place. MindMed sees a massive opportunity by having a diverse psychedelic pipeline. Rather than focusing on a single compound, MindMed’s […]

Schwierige Woche, positives Ende. Unter starken Schwankungen erzielte der Dax in der Vorwoche noch ein leichtes Plus - der Fed sei Dank. Bei den Einzelwerten könnte Adidas einen Käufer für die US-Tochter Reebok gefunden haben. Dazu gab es Trouble im Krypto-Paradise nach Elon Musks Entscheidung, Bitcoin nicht mehr als Zahlungsmittel zu akzeptieren. Der Glore Fonds (WKN: A14N9A) investiert in E-Commerce - und war mit der Strategie besonders im Corona-Jahr 2020 äußerst erfolgreich. Initiator Jochen Krisch verrät unter anderem, welche Aktien aus dem Sektor weiterhin für Aufsehen sorgen dürften. MDMA und Mushrooms gegen Depression und Angststörungen? Mit dieser Idee beschäftigen sich in den USA zahlreiche Startups. Mindmed (WKN: A2P09G) und Compass Pathways (WKN: A2QCDR) sind börsennotierte Firmen in dem Bereich, deren bisherige Performance enttäuscht. Die Aktien könnten aber eine große Wette auf die Zukunft sein. Diesen Podcast der Podstars GmbH (Philipp Westermeyer) vom 17.05.2021, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

LSD and magic mushrooms are now publicly traded because MindMed’s psychedelics found a trend. Sony’s whipping up Playstations to become the arms dealer in the Streaming Wars. And McDonald’s fried chicken sandwich just got the CIA treatment. $MNMD $SONY $MCD Got a SnackFact? Tweet it @RobinhoodSnacks @JackKramer @NickOfNewYork Want a shoutout on the pod? Fill out this form: https://forms.gle/KhUAo31xmkSdeynD9 Got a SnackFact for the pod? We got a form for that too: https://docs.google.com/forms/d/e/1FAIpQLSe64VKtvMNDPGSncHDRF07W34cPMDO3N8Y4DpmNP_kweC58tw/viewform Learn more about your ad choices. Visit podcastchoices.com/adchoices

Atai Life Sciences is the most highly anticipated psychedelic IPO of 2021. It has a pipeline of 10 drugs, owns a large piece of Compass Pathways, and is also researching digital therapeutics and brain computer interfaces. When it IPOs it will likely be the psychedelic company with the largest market cap. In this episode of Brom Talks, we peek behind the curtain of Atai, and try to see if this valuation is justified. In doing so, we answer questions like: Who is Christian Angermayer? What does Atai's pipeline look like? What are the implications of Atai's unorthodox corporate structure? It is even fair to call Atai a psychedelics company? And we also compare and contrast this company with MindMed.

Julia Chatterley is live from New York. Here are the top business news stories today! Bitcoin boost! Crypto gains help drive Tesla to record profits. Fund fiasco! The Archegos collapse costs banks over $10 billion. Mind over matter! MindMed the psychedelic medicine biotech company makes public debut on the NASDAQ. It’s Tuesday, let’s make a move.To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Sa'ad Shah is the co-founder and managing partner of Noetic, a venture capital firm that seeks to invest in emerging and early-stage psychedelic-based wellness, therapeutic and pharmaceutical companies. JR Rahn is the co-founder and co-CEO of MindMed, a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. Psychedelics in medicine represent an entirely new biotech asset class. Psychedelics still carry with it the stigma of its recreational use in the 60s and 70s, but its application as therapy is intended to help people with mental health and addiction issues. Psychedelic-assisted therapy involves a trained therapist who guides the patient through the experience. "The science has been incredibly compelling. The efficacy rates cannot be ignored." ————————————————————————— To learn more about this episode, including podcast transcripts and show notes, visit *salt.org/talks* ( http://salt.org/talks ) Moderated by Anthony Scaramucci.

This is part two of my MindMed Deep Dive. The primary focus of this video is an analysis of MindMed's acquisition of HealthMode. I also clear up a few things from the last video. Did the HealthMode acquisition make sense for MMED? What are their true AI / ML capabilities? Did I sell any shares after the last video? Clarification on my opinion on Departures Capital. Watch the video here: https://youtu.be/LUnEIRZmegE Part 1 is here (https://youtu.be/cfqdvm_Bz-w​).

Many of us have already 10x'd our money on MindMedicine (MMED / MMEDF): should we take our profits now or hold for the next 10 years? Brom dives deep into this topic and looks at questions like: Will the Nasdaq uplisting happen? Is MindMed's drug development pipeline strong? Why is MindMed associated with sketchy pump and dump groups like Departures Capital and Market Jar Media? Do they have a way to capitalize on their research? WTF is Kevin O'Leary doing in a drug company? Why did JR Rahn sell his shares? Does MindMed Founder and CEO JR Rahn have the right qualifications? Is MindMed's team a winning team? Watch on YouTube https://www.youtube.com/playlist?list=PLSojjMXxr79FMrXF5ocZ5Qy5uEQ78FQJG Listen to this video on Spotify: https://open.spotify.com/show/1nVnMFaYNmln6fwk63B9kd Listen to this video on other Podcast Platforms: https://anchor.fm/brom1 Brom on Instagram: https://www.instagram.com/brom_qr/channel/ Brom on Twitter: https://twitter.com/therealbrom Brom's personal website: https://brom.ai

Today on Health in 2 Point 00, Jess makes Matthew pronounce some impossible words while we cover lots of funding deals. Redox has raised $45 million in a Series D, bringing their total up to $95 million. Nanit, another baby monitoring company, raises $25 million in a Series C, Innovaccer raises a $105 million D round, and psychedelic biotech company MindMed acquires digital health company HealthMode.

Psychedelic Therapy is in our future, the leaders in this field are currently Compass Pathways, MindMed and Entheon Biomedical.  They are being baked by investors like Peter Thiel and Kevin O'Leary.  In this video we'll take a closer look at what the future may look like.Welcome back, tribe members! Today I'm discussing "A New Biotech Industry is Born, Where Do You Invest Now?". If you enjoy this video feel free to SUBSCRIBE! Make sure to follow me on social media for even more coverage of the stock market.Link to our Discord: https://discord.io/bestofusFollow Me: Facebook: https://www.facebook.com/BestofUSLLC/Instagram: https://www.instagram.com/bestofusinv...Twitter: https://twitter.com/BestOfUsInvestSubscribe:https://www.youtube.com/channel/UC-hq...We have Up-Graded Our Discord: Kerry's Portfolio, Trades and InsightsThis is the new link: https://discord.io/bestofus. It is now organized by topics and will be easier to navigate and communicate.

Psychedelics have long been viewed as having potential to treat a range of mental health disorders including depression, addiction, PTSD, and ADHD. Government policies, though, have long impeded studies of their benefits. Mind Medicine is developing a pipeline of therapies based on psychedelics in the hopes of developing needed medicines for psychiatric conditions. Its lead experimental therapy is an ibogaine-derived molecule for the treatment of opioid addiction. We spoke to Steve Hurst, founder and CEO of MindMed, about the potential for psychedelic-based medicines, what's known about them to date, and the challenges of working with these substances.